Doximity, Inc.

Informe acción NYSE:DOCS

Capitalización de mercado: US$4.6b

Doximity Resultados de beneficios anteriores

Pasado controles de criterios 3/6

Doximity ha aumentado sus beneficios a una tasa media anual de 42%, mientras que los beneficios de la industria de Healthcare Services han experimentado un crecimiento de 2.8% anual. Los ingresos han ido creciendo a una tasa media de 29.1% al año. La rentabilidad financiera de Doximity es de 15.9%, y sus márgenes netos son de 29.4%.

Información clave

42.0%

Tasa de crecimiento de los beneficios

29.6%

Tasa de crecimiento del BPA

Crecimiento de la industria Healthcare Services 1.7%
Tasa de crecimiento de los ingresos29.1%
Rentabilidad financiera15.9%
Margen neto29.4%
Última actualización de beneficios31 Dec 2023

Actualizaciones de resultados anteriores recientes

We Like Doximity's (NYSE:DOCS) Earnings For More Than Just Statutory Profit

Feb 15
We Like Doximity's (NYSE:DOCS) Earnings For More Than Just Statutory Profit

Recent updates

With Doximity, Inc. (NYSE:DOCS) It Looks Like You'll Get What You Pay For

Apr 16
With Doximity, Inc. (NYSE:DOCS) It Looks Like You'll Get What You Pay For

Estimating The Fair Value Of Doximity, Inc. (NYSE:DOCS)

Mar 26
Estimating The Fair Value Of Doximity, Inc. (NYSE:DOCS)

Doximity: Rating Upgrade To Buy As Outlook Turns Positive

Feb 21

We Like Doximity's (NYSE:DOCS) Earnings For More Than Just Statutory Profit

Feb 15
We Like Doximity's (NYSE:DOCS) Earnings For More Than Just Statutory Profit

What Is Doximity, Inc.'s (NYSE:DOCS) Share Price Doing?

Feb 13
What Is Doximity, Inc.'s (NYSE:DOCS) Share Price Doing?

Doximity: Downside Is Contained, While Upside Depends On Management's Game Plan

Jan 16

Doximity (NYSE:DOCS) May Have Issues Allocating Its Capital

Jan 04
Doximity (NYSE:DOCS) May Have Issues Allocating Its Capital

Doximity, Inc.'s (NYSE:DOCS) Intrinsic Value Is Potentially 29% Above Its Share Price

Dec 14
Doximity, Inc.'s (NYSE:DOCS) Intrinsic Value Is Potentially 29% Above Its Share Price

Doximity Earnings: Steer Clear Of This Rollercoaster War Of Optimism Vs. Skepticism

Nov 10

Doximity: Adding Value Using AI But Faces Near-Term Risks

Nov 01

Is Doximity, Inc. (NYSE:DOCS) Potentially Undervalued?

Oct 30
Is Doximity, Inc. (NYSE:DOCS) Potentially Undervalued?

Doximity (NYSE:DOCS) Might Be Having Difficulty Using Its Capital Effectively

Sep 25
Doximity (NYSE:DOCS) Might Be Having Difficulty Using Its Capital Effectively

Doximity: Rating Downgrade As Investors Shift Focus To The Near-Term Outlook

Aug 24

Doximity Earnings: Too Many Problems, Sell

Aug 09

A Look At The Intrinsic Value Of Doximity, Inc. (NYSE:DOCS)

Jul 29
A Look At The Intrinsic Value Of Doximity, Inc. (NYSE:DOCS)

Why Doximity, Inc. (NYSE:DOCS) Could Be Worth Watching

Jul 09
Why Doximity, Inc. (NYSE:DOCS) Could Be Worth Watching

Doximity: Continue To See Positive Upside From Current Stock Level

Jul 05

The Returns At Doximity (NYSE:DOCS) Aren't Growing

Jun 21
The Returns At Doximity (NYSE:DOCS) Aren't Growing

Doximity: Digital Health Play With Strong Fundamentals

Jun 21

A Look At The Fair Value Of Doximity, Inc. (NYSE:DOCS)

Apr 07
A Look At The Fair Value Of Doximity, Inc. (NYSE:DOCS)

Doximity (NYSE:DOCS) Is Reinvesting At Lower Rates Of Return

Mar 20
Doximity (NYSE:DOCS) Is Reinvesting At Lower Rates Of Return

Doximity: Good Business But Extremely Overvalued

Feb 18

Doximity Q3 Earnings: Disappointing Results

Feb 10

Calculating The Fair Value Of Doximity, Inc. (NYSE:DOCS)

Dec 25
Calculating The Fair Value Of Doximity, Inc. (NYSE:DOCS)

Doximity: On The Right Path To Further Consolidate Market Share

Dec 22

Here's What's Concerning About Doximity's (NYSE:DOCS) Returns On Capital

Dec 04
Here's What's Concerning About Doximity's (NYSE:DOCS) Returns On Capital

Doximity up 16% after fiscal 2023 Q2 beats, FY revenue range includes consensus

Nov 10

Doximity, down 9%, falls below IPO price

Oct 12

Doximity Appears Well-Positioned But Shares May Be Fully Valued Here

Aug 11

Doximity Non-GAAP EPS of $0.14 beats by $0.03, revenue of $90.6M beats by $0.95M

Aug 04

Unpleasant Surprises Could Be In Store For Doximity, Inc.'s (NYSE:DOCS) Shares

Jul 09
Unpleasant Surprises Could Be In Store For Doximity, Inc.'s (NYSE:DOCS) Shares

Pair Trade: Going Long Doximity And Short Teladoc

Jul 05

Doximity: Slowing Guidance, Stock Drops, But It Oozes Cash Flows

May 18

Doximity: Turning Bullish After Stock Price Correction

Apr 01

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Doximity. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).


Historial de beneficios e ingresos

NYSE:DOCS Ingresos, gastos y beneficios (USD Millions)
FechaIngresosBeneficiosGastos G+AGastos de I+D
31 Dec 2346813816983
30 Sep 2344812316784
30 Jun 2343711916683
31 Mar 2341911316080
31 Dec 2240211915376
30 Sep 2238414114672
30 Jun 2236214813868
31 Mar 2234413312862
31 Dec 2131710711457
30 Sep 212775710153
30 Jun 21243308847
31 Mar 21207227844
31 Dec 20177146740
31 Mar 20116114632
31 Mar 198614027

Ingresos de calidad: DOCS tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio(29.4%) de DOCS son inferiores a los del año pasado (29.7%).


Análisis del flujo de caja libre vs. Beneficios


Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: En los últimos 5 años, los beneficios de lDOCS han crecido significativamente en un 42% al año.

Acelerando crecimiento: El crecimiento de los beneficios de DOCS en el último año (15.4%) está por debajo de su media de 5 años (42% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de DOCS en el último año (15.4%) superó al de la industria Healthcare Services 15.4%.


Rentabilidad financiera

Alta ROE: La rentabilidad financiera de DOCS (15.9%) se considera baja.


Rentabilidad económica


Rendimiento del capital invertido


Descubre empresas con buenos resultados en el pasado

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target